Cumberland Pharmaceuticals (CPIX) Receivables (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Receivables across 17 years of filings, most recently posting $14.3 million for Q1 2026.

• Receivables for Q1 2026 came in at $14.3 million, up 35.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.3 million (up 35.98% YoY), and the FY2025 annual result was $16.9 million, up 44.81% from the prior year.
• Receivables came in at $14.3 million for Q1 2026 at Cumberland Pharmaceuticals, down from $16.9 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $16.9 million in Q4 2025 to a low of $9.8 million in Q4 2023.
• The 5-year median for Receivables is $12.2 million (2023), against an average of $12.5 million.
• Across the five-year window, Receivables surged 91.41% in 2022 and slipped 26.72% in 2024, its largest moves.
• Cumberland Pharmaceuticals' Receivables stood at $13.2 million in 2022, then dropped by 25.87% to $9.8 million in 2023, then grew by 19.91% to $11.7 million in 2024, then soared by 44.81% to $16.9 million in 2025, then declined by 15.83% to $14.3 million in 2026.
• The last three Receivables figures came in at $14.3 million (Q1 2026), $16.9 million (Q4 2025), and $10.4 million (Q3 2025), per Business Quant data.